|
|
ASH 2009: Jean-Luc Harousseau
Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM)
Jean-Luc Harousseau, MD
Centre René Gauducheau
Nantes/St Herblain, France
|
|
ASH 2009: Andrzej J Jakubowiak
Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results
ASH 2009: Andrzej J. Jakubowiak
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial
ASh 2009: Andrzej Jakubowiak
Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ)
ASH 2009: Asher Chanan-Khan
Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
ASH 2009: Asher Chanan-Khan
Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis
ASH 2009: Attaya Suvannasankha
Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients
ASH2009: Brian Durie, Bank On A Cure® Update
ASH2009: Gareth Morgan, Bank On A Cure® Update
Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma
ASH 2009: Craig Reeder
A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity
ASH 2009: Don Benson
Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results
ASH 2009: Elena Zamagni
Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study
ASH 2009: Evangelos Terpos
Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis
ASH 2009: Evangelos Terpos
High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma
ASH 2009: Evangelos Terpos
Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities
ASH 2009: Evangelos Terpos
The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients
ASH 2009: Federica Cavallo
A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients
ASH 2009: Francesca Gay
Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma
ASH 2009: Francesca Gay
Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients
ASH 2009: Francesca Gay
Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients
ASH 2009: Francesca Gay
The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy
ASH 2009: Irene Ghobrial
Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma
ASH 2009: Jesús San Miguel
A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma
ASH 2009: Joseph R. Mikhael
Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma
ASH 2009: Kai Neben
Achievement of CR and nCR Before and After First High-Dose Therapy Followed by Autologous Stem Cell Transplantation Is a Major Marker for Long-Term Survival in Multiple Myeloma Patients
Our apologies, this video is in process and will be posted in the near future.
ASH 2009: Michele Cavo
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD
ASH 2009: Philip McCarthy
Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
ASH 2009: Prashant Kapoor
Evidence for Cytogenetic and Fluorescence in Situ Hybridization (FISH) Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies
ASH 2009: Prashant Kapoor
Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
ASH 2009: Preeti Khetarpal
The Impact of Withholding Immunomodulatory Drugs for Stem Cell Mobilization On Disease Activity in Multiple Myeloma
ASH 2009: Rachid Baz
Evaluation of Single Agent Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
ASH 2009: Ravi Vij
Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects
Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma
ASH 2009: Swaminathan Padmanabhan
A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx)
ASH 2009: Taimur Sher
Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study
ASH 2009: Tomer Mark
T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma
ASH 2009: Tommasina Guglielmelli
Sequential Therapy with IMID’s in Relapsed-Refractory Multiple Myeloma Patients
ASH 2009: Ulf-Henrik Mellqvist
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
Dr. Morie Gertz, Mayo Clinic, Rochester, Minnesota
Dr. Vincent Rajkumar, Mayo Clinic, Rochester, Minnesota
Neues vom ASH Kongress 2009
Un resumen de las presentaciones de ASH 2009
Una visione d’insieme dell’ASH 2009: Antonio Palumbo
Richardson Sequential vs. Combinations
Update from ASH 2009:
Sequential Use of Treatments vs. Combinations
Update from ASH 2009
Treating Elderly Patients
Update from ASH 2009
The Role of Transplant
Update from ASH 2009
Treating Younger Patients
ASCO 2010: A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
ASH 2009: Dr. Brian Durie, Cedars Sinai Comprehensive Cancer Center, Los Angeles, California
ASH 2009: Paul Richardson, Dana Farber Cancer Institute, Boston, Massachusetts
ASH 2009: Sundar Jagannath, Overview
Dr. Morie Gertz, Mayo Clinic, Rochester, Minnesota
Dr. Vincent Rajkumar, Mayo Clinic, Rochester, Minnesota
Update from ASH 2009:
Novel Agents
Neues vom ASH Kongress 2009
Un resumen de las presentaciones de ASH 2009
Una visione d’insieme dell’ASH 2009: Antonio Palumbo
ASH 2009: Vincent Rajkumar, Current Approaches To Treatment Of Myeloma
Update From ASH 2009: Sequential Use Of Treatments vs.Combinations
Update from ASH 2009:
Sequential Use of Treatments vs. Combinations
Update from ASH 2009
Treating Elderly Patients
Update from ASH 2009
The Role of Transplant
Update from ASH 2009
Treating Younger Patients
ASH 2009: Andrzej J. Jakubowiak
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial
ASH 2009: Antonio Palumbo
A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma
ASH 2009: Antonio Palumbo
A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200 Mg/M2) and Autologous Transplantation (Mel200) in Newly Diagnosed Myeloma Patients: An Interim Analysis
ASH 2009: Attaya Suvannasankha
Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients
ASH 2009: Choon Kee Lee
An Outcome Study On Survival and Disease Control in Patients with High-Risk Multiple Myeloma (MM) for Relapse, Treated with High-Dose Melphalan Combined with Bortezomib for Autotransplant Followed by Post-Transplant Maintenance with Bortezomib and Lenalidomide
ASH 2009: Edward Agura
Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study
ASH 2009: Evangelos Terpos
High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma
ASH 2009: Evangelos Terpos
Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment
ASH 2009: Evangelos Terpos
Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities
ASH 2009: Evangelos Terpos
The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients
ASH 2009: Federica Cavallo
A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients
ASH 2009: Francesca Gay
Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma
ASH 2009: Francesca Gay
Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients
ASH 2009: Francesca Gay
Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma
ASH 2009: Maria-Victoria Mateos
Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis
ASH 2009: Paul Richardson
High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study
ASH 2009: Philip McCarthy
Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events
ASH 2009: Preeti Khetarpal
The Impact of Withholding Immunomodulatory Drugs for Stem Cell Mobilization On Disease Activity in Multiple Myeloma
ASH 2009: Rachid Baz
Evaluation of Single Agent Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
ASH 2009: Ruben Niesvizky
Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM)
ASH 2009: Sagar Lonial
Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results
ASH 2009: Shaji Kumar
Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation
ASH 2009: Shaji Kumar
Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study
ASH 2009: Tommasina Guglielmelli
Sequential Therapy with IMID’s in Relapsed-Refractory Multiple Myeloma Patients
ASH 2009: Antonio Palumbo
Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients
ASH 2009: Elena Zamagni
Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study
ASH 2009: Evangelos Terpos
Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis
ASH 2009: Evangelos Terpos
Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis
ASH 2009: Federica Cavallo
A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients
ASH 2009: Francesca Gay
Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma
ASH 2009: Gareth Morgan
Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations
ASH 2009: Gareth Morgan
The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS
ASH 2009: Heinz Ludwig
Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial
ASH 2009: Heinz Ludwig
Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma
ASH 2009: Jean-Luc Harousseau
Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM)
ASH 2009: Joan Bladé
Thalidomide/Dexamethasone (TD) Vs. Bortezomib (Velcade®)/Thalidomide/Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade® as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial
ASH 2009: Maria-Victoria Mateos
A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years
ASH 2009: Meral Beksac
Addition of Thalidomide (T) to Oral Melphalan/Prednisone (MP) in Patients with Multiple Myeloma: Initial Results of a Randomized Trial From the Turkish Myeloma Study Group
ASH 2009: Michele Cavo
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD
ASH 2009: Nilanjan Ghosh
Bortezomib and Thalidomide, a Steroid Free Regimen in Newly Diagnosed Patients with Multiple Myeloma
ASH 2009: Prashant Kapoor
Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
ASH 2009: Preeti Khetarpal
The Impact of Withholding Immunomodulatory Drugs for Stem Cell Mobilization On Disease Activity in Multiple Myeloma
ASH 2009: Shaji Kumar
Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study
ASH 2009: Shaji Kumar
Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation
ASH 2009: Taimur Sher
Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study
ASH 2009: Tomer Mark
T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma
ASH 2009: Tommasina Guglielmelli
Sequential Therapy with IMID’s in Relapsed-Refractory Multiple Myeloma Patients
Myeloma Today Summer 2009
Myeloma Today Summer 2009
ASH 2009: Andrzej J Jakubowiak
Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results
ASH 2009: Andrzej J. Jakubowiak
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial
ASH 2009: Antonio Palumbo
Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients
ASH 2009: Choon Kee Lee
An Outcome Study On Survival and Disease Control in Patients with High-Risk Multiple Myeloma (MM) for Relapse, Treated with High-Dose Melphalan Combined with Bortezomib for Autotransplant Followed by Post-Transplant Maintenance with Bortezomib and Lenalidomide
ASH 2009: Craig Reeder
A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity
ASH 2009: David Siegel
Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma
ASH 2009: Eric Sanchez
Alpha Lipoic Acid (ALA) Inhibits the Anti-Myeloma Effects of Bortezomib
ASH 2009: Evangelos Terpos
Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis
ASH 2009: Evangelos Terpos
Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities
ASH 2009: Evangelos Terpos
The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients
ASH 2009: Francesca Gay
Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients
ASH 2009: Francesca Gay
The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy
ASH 2009: Heinz Ludwig
Bortezomib-Doxorubicin-Dexamethasone (BDD) in Patients with Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Final Results of a Phase II Study
ASH 2009: Heinz Ludwig
Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial
ASH 2009: Hervé Avet Loiseau
Induction with Velcade®/Dexamethasone Partially Overcomes the Poor Prognosis of t(4;14), but Not That of Del(17p), in Young Patients with Multiple Myeloma
ASH 2009: Jean-Luc Harousseau
Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM)
ASH 2009: Jean-Luc Harousseau
High Complete and Very Good Partial Response Rates with Bortezomib–Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial
ASH 2009: Jesús San Miguel
A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma
ASH 2009: Joan Bladé
Thalidomide/Dexamethasone (TD) Vs. Bortezomib (Velcade®)/Thalidomide/Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade® as Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Phase III PETHEMA/GEM Trial
ASH 2009: Maria-Victoria Mateos
A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years
ASH 2009: Maria-Victoria Mateos
Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years’ Follow-up and Extensive Subsequent Therapy Use
ASH 2009: Michele Cavo
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD
ASH 2009: Nilanjan Ghosh
Bortezomib and Thalidomide, a Steroid Free Regimen in Newly Diagnosed Patients with Multiple Myeloma
ASH 2009: Paul Richardson
Bortezomib-Associated Peripheral Neuropathy: Relationship Between Clinical Neurophysiologic Evidence in Previously Untreated Multiple Myeloma Patients and Preclinical Characterization in a Mouse Model
ASH 2009: Paul Richardson
High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study
ASH 2009: Paul Richardson
Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results
ASH 2009: Paul Richardson
Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study
ASH 2009: Pieter Sonneveld
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
ASH 2009: Ruben Niesvizky
Phase 3b UPFRONT Study: Interim Results From a Community Practice-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients
ASH 2009: Sagar Lonial
A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma
ASH 2009: Sagar Lonial
Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone
ASH 2009: Shaji Kumar
Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study
ASH 2009: Shaji Kumar
Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study
ASH 2009: Sophie L. Corthals
Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma
ASH 2009: Sophie L. Corthals
Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma
ASH 2009: Sundar Jagannath
The Combination of Vorinostat and Bortezomib Provides Long-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
ASH 2009: Taimur Sher
Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study
ASH 2009: Tomer Mark
T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma
ASH 2009: Ulf-Henrik Mellqvist
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
ASH 2009: Andrzej J Jakubowiak
Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results
ASh 2009: Andrzej Jakubowiak
Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ)
ASH 2009: Asher Chanan-Khan
Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
ASH 2009: Asher Chanan-Khan
Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis
ASH 2009: David Siegel
Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study
ASH 2009: David Siegel
PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort
ASH 2009: David Siegel
Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma
ASH 2009: Don Benson
Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results
ASH 2009: Edward Agura
Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study
ASH 2009: Heinz Ludwig
Bortezomib-Doxorubicin-Dexamethasone (BDD) in Patients with Acute Light Chain Induced Renal Failure (ARF) in Multiple Myeloma (MM). Final Results of a Phase II Study
ASH 2009: Irene Ghobrial
Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma
ASH 2009: Jesús San Miguel
A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma
ASH 2009: Paul Richardson
A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib
ASH 2009: Paul Richardson
Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results
ASH 2009: Paul Richardson
Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM)
ASH 2009: Paul Richardson
Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study
ASH 2009: Ravi Vij
Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects
ASH 2009: Ruben Niesvizky
Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM)
ASH 2009: Sagar Lonial
A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma
ASH 2009: Sagar Lonial
Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results
ASH 2009: Sundar Jagannath
The Combination of Vorinostat and Bortezomib Provides Long-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
ASH 2009: Swaminathan Padmanabhan
A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx)
ASH 2009: Antonio Palumbo
A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200 Mg/M2) and Autologous Transplantation (Mel200) in Newly Diagnosed Myeloma Patients: An Interim Analysis
ASH 2009: Choon Kee Lee
An Outcome Study On Survival and Disease Control in Patients with High-Risk Multiple Myeloma (MM) for Relapse, Treated with High-Dose Melphalan Combined with Bortezomib for Autotransplant Followed by Post-Transplant Maintenance with Bortezomib and Lenalidomide
ASH 2009: Elena Zamagni
Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study
ASH 2009: Evangelos Terpos
Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis
ASH 2009: Francesca Gay
Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients
ASH 2009: Joseph R. Mikhael
Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma
ASH 2009: Kai Neben
Achievement of CR and nCR Before and After First High-Dose Therapy Followed by Autologous Stem Cell Transplantation Is a Major Marker for Long-Term Survival in Multiple Myeloma Patients
ASH 2009: Michele Cavo
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD
ASH 2009: Morie Gertz, Stem Cell Transplant in Multiple Myeloma: Impact of Response Failure in the Era of Novel Therapies
ASH 2009: Nina Shah
Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma
ASH 2009: Philip McCarthy
Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events
ASH 2009: Preeti Khetarpal
The Impact of Withholding Immunomodulatory Drugs for Stem Cell Mobilization On Disease Activity in Multiple Myeloma
ASH 2009: Shaji Kumar
Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation
ASH 2009: Andrzej J. Jakubowiak
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial
ASH 2009: Antonio Palumbo
Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients
ASH 2009: Antonio Palumbo
A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma
ASH 2009: Antonio Palumbo
A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200 Mg/M2) and Autologous Transplantation (Mel200) in Newly Diagnosed Myeloma Patients: An Interim Analysis
ASH 2009: Attaya Suvannasankha
Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients
ASH 2009: Craig Reeder
A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity
ASH 2009: Evangelos Terpos
High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma
ASH 2009: Francesca Gay
Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma
ASH 2009: Francesca Gay
Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients
ASH 2009: Francesca Gay
Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma
ASH 2009: Gareth Morgan
The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS
ASH 2009: Heinz Ludwig
Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial
ASH 2009: Heinz Ludwig
Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma
ASH 2009: Jean-Luc Harousseau
Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM)
ASH 2009: Jean-Luc Harousseau
High Complete and Very Good Partial Response Rates with Bortezomib–Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial
ASH 2009: Maria-Victoria Mateos
A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years
ASH 2009: Maria-Victoria Mateos
Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years’ Follow-up and Extensive Subsequent Therapy Use
ASH 2009: Maria-Victoria Mateos
Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis
ASH 2009: Meral Beksac
Addition of Thalidomide (T) to Oral Melphalan/Prednisone (MP) in Patients with Multiple Myeloma: Initial Results of a Randomized Trial From the Turkish Myeloma Study Group
ASH 2009: Paul Richardson
High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study
ASH 2009: Prashant Kapoor
Evidence for Cytogenetic and Fluorescence in Situ Hybridization (FISH) Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies
ASH 2009: Rachid Baz
Evaluation of Single Agent Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
ASH 2009: Ruben Niesvizky
Phase 3b UPFRONT Study: Interim Results From a Community Practice-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients
ASH 2009: Taimur Sher
Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study
ASH 2009: Tomer Mark
T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma
ASH 2009: Andrzej J Jakubowiak
Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results
ASh 2009: Andrzej Jakubowiak
Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ)
ASH 2009: Asher Chanan-Khan
Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
ASH 2009: Asher Chanan-Khan
Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis
ASH 2009: David Siegel
Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study
ASH 2009: David Siegel
PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort
ASH 2009: David Siegel
Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma
ASH 2009: Evangelos Terpos
Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment
ASH 2009: Evangelos Terpos
Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities
ASH 2009: Evangelos Terpos
The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients
ASH 2009: Federica Cavallo
A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients
ASH 2009: Jesús San Miguel
A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma
ASH 2009: Paul Richardson
A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib
ASH 2009: Paul Richardson
Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results
ASH 2009: Paul Richardson
Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM)
ASH 2009: Paul Richardson
Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study
ASH 2009: Ravi Vij
Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects
ASH 2009: Ruben Niesvizky
Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM)
ASH 2009: Sagar Lonial
A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma
ASH 2009: Sagar Lonial
Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results
ASH 2009: Sundar Jagannath
The Combination of Vorinostat and Bortezomib Provides Long-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
ASH 2009: Swaminathan Padmanabhan
A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx)
The International Myeloma Foundation Welcomes Entertainment Industry Executive Amy Weiss to Board of Directors
The International Myeloma Foundation Welcomes Entertainment Industry Executive Amy Weiss to Board of Directors
ASH 2009: Brian Durie
Bank On A Cure®
ASH 2009: Gareth Morgan, Bank On A Cure®
ASH 2009: Gareth Morgan
Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations
ASH 2009: Pieter Sonneveld
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
ASH 2009: Sophie L. Corthals
Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma
ASH 2009: Sophie L. Corthals
Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma
ASH 2009: Evangelos Terpos
High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma
ASH 2009: Evangelos Terpos
High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma
ASH 2009: Herve Avet-Loiseau
Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients
ASH 2009: Mariateresa Fulciniti
Gadolinium Containing Contrast Agent Promotes Multiple Myeloma Cell Growth: Implication for Clinical Use of MRI in Myeloma
ASH 2009: Martin Ellis
Novel Association Between Thyroid Hormones and Multiple Myeloma Cell Proliferation: a MAPK Dependent Activity
ASH 2009: Masood Shammas
Evolution of Genomic Changes and Their Significance in Myeloma
ASH 2009: Prashant Kapoor
Evidence for Cytogenetic and Fluorescence in Situ Hybridization (FISH) Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies
ASH 2009: Andrzej J Jakubowiak
Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results
ASH 2009: Andrzej J. Jakubowiak
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial
ASh 2009: Andrzej Jakubowiak
Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ)
ASH 2009: Antonio Palumbo
Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients
ASH 2009: Antonio Palumbo
A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma
ASH 2009: Antonio Palumbo
A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200 Mg/M2) and Autologous Transplantation (Mel200) in Newly Diagnosed Myeloma Patients: An Interim Analysis
ASH 2009: Asher Chanan-Khan
Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
ASH 2009: Asher Chanan-Khan
Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis
ASH 2009: Attaya Suvannasankha
Phase 2 Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP) for Newly Diagnosed Multiple Myeloma Patients
ASH 2009: Bank On A Cure®
ASH 2009: Brian Durie
Bank On A Cure®
ASH 2009: Choon Kee Lee
An Outcome Study On Survival and Disease Control in Patients with High-Risk Multiple Myeloma (MM) for Relapse, Treated with High-Dose Melphalan Combined with Bortezomib for Autotransplant Followed by Post-Transplant Maintenance with Bortezomib and Lenalidomide
ASH 2009: Craig Reeder
A Phase II Trial Comparison of Once Versus Twice Weekly Bortezomib in CYBORD Chemotherapy for Newly Diagnosed Myeloma: Identical High Response Rates and Less Toxicity
ASH 2009: David Siegel
Combined Vorinostat, Lenalidomide and Dexamethasone Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase I Study
ASH 2009: David Siegel
PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort
ASH 2009: David Siegel
Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma
ASH 2009: Don Benson
Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results
ASH 2009: Edward Agura
Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study
ASH 2009: Elena Zamagni
Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study
ASH 2009: Eric Sanchez
Alpha Lipoic Acid (ALA) Inhibits the Anti-Myeloma Effects of Bortezomib
ASH 2009: Evangelos Terpos
Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis
ASH 2009: Evangelos Terpos
High Serum Lactate Dehydrogenase (LDH) Is An Important Prognostic Factor in the Era of Novel Agents and Adds to the Prognostic Value of the International Staging System (ISS) in Patients with Multiple Myeloma
ASH 2009: Evangelos Terpos
Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities
ASH 2009: Evangelos Terpos
The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients
ASH 2009: Federica Cavallo
A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients
ASH 2009: Francesca Gay
Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma
ASH 2009: Francesca Gay
Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients
ASH 2009: Francesca Gay
Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients
ASH 2009: Francesca Gay
The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy
ASH 2009: Gareth Morgan, Bank On A Cure®
ASH 2009: Gareth Morgan
Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations
ASH 2009: Gareth Morgan
The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS
ASH 2009: Hayley Knollman, Infusion of Large Number of Circulating Myeloma Cells Does Not Influence the Survival of Patients Undergoing Autologous Stem Cell Transplantation
ASH 2009: Heinz Ludwig
Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial
ASH 2009: Heinz Ludwig
Thalidomide-Interferon Vs. Interferon Maintenance Therapy After Thal-Dex Vs. MP Induction Therapy in Elderly Patients with Multiple Myeloma
ASH 2009: Hervé Avet Loiseau
Induction with Velcade®/Dexamethasone Partially Overcomes the Poor Prognosis of t(4;14), but Not That of Del(17p), in Young Patients with Multiple Myeloma
ASH 2009: Herve Avet-Loiseau
Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients
ASH 2009: Irene Ghobrial
Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma
ASH 2009: Jean-Luc Harousseau
High Complete and Very Good Partial Response Rates with Bortezomib–Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial
ASH 2009: Jesús San Miguel
A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma
ASH 2009: Joseph R. Mikhael
Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma
ASH 2009: Kai Neben
Achievement of CR and nCR Before and After First High-Dose Therapy Followed by Autologous Stem Cell Transplantation Is a Major Marker for Long-Term Survival in Multiple Myeloma Patients
ASH 2009: Maria-Victoria Mateos
A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years
ASH 2009: Maria-Victoria Mateos
Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years’ Follow-up and Extensive Subsequent Therapy Use
ASH 2009: Maria-Victoria Mateos
Multicenter, Randomized, Open-Label, Phase III Trial of Lenalidomide-Dexamethasone (Len/dex) Vs Therapeutic Abstention in Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic MM: Results of the First Interim Analysis
ASH 2009: Mariateresa Fulciniti
Gadolinium Containing Contrast Agent Promotes Multiple Myeloma Cell Growth: Implication for Clinical Use of MRI in Myeloma
ASH 2009: Martin Ellis
Novel Association Between Thyroid Hormones and Multiple Myeloma Cell Proliferation: a MAPK Dependent Activity
ASH 2009: Masood Shammas
Evolution of Genomic Changes and Their Significance in Myeloma
ASH 2009: Meral Beksac
Addition of Thalidomide (T) to Oral Melphalan/Prednisone (MP) in Patients with Multiple Myeloma: Initial Results of a Randomized Trial From the Turkish Myeloma Study Group
ASH 2009: Michele Cavo
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD
ASH 2009: Morie Gertz, Stem Cell Transplant in Multiple Myeloma: Impact of Response Failure in the Era of Novel Therapies
ASH 2009: Nilanjan Ghosh
Bortezomib and Thalidomide, a Steroid Free Regimen in Newly Diagnosed Patients with Multiple Myeloma
ASH 2009: Nina Shah
Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma
ASH 2009: Paul Richardson, Dana Farber Cancer Institute, Boston, Massachusetts
ASH 2009: Paul Richardson
A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib
ASH 2009: Paul Richardson
Bortezomib-Associated Peripheral Neuropathy: Relationship Between Clinical Neurophysiologic Evidence in Previously Untreated Multiple Myeloma Patients and Preclinical Characterization in a Mouse Model
ASH 2009: Paul Richardson
High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study
ASH 2009: Paul Richardson
Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results
ASH 2009: Paul Richardson
Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM)
ASH 2009: Paul Richardson
Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study
ASH 2009: Philip McCarthy
Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events
ASH 2009: Pieter Sonneveld
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
ASH 2009: Prashant Kapoor
Evidence for Cytogenetic and Fluorescence in Situ Hybridization (FISH) Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies
ASH 2009: Prashant Kapoor
Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
ASH 2009: Preeti Khetarpal
The Impact of Withholding Immunomodulatory Drugs for Stem Cell Mobilization On Disease Activity in Multiple Myeloma
ASH 2009: Rachid Baz
Evaluation of Single Agent Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
ASH 2009: Ravi Vij
Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects
ASH 2009: Ruben Niesvizky
Phase Ib Multicenter Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM)
ASH 2009: Ruben Niesvizky
Phase 3b UPFRONT Study: Interim Results From a Community Practice-Based Prospective Randomized Trial Evaluating Three Bortezomib-Based Regimens in Elderly, Newly Diagnosed Multiple Myeloma Patients
ASH 2009: Sagar Lonial
A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma
ASH 2009: Sagar Lonial
Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone
ASH 2009: Sagar Lonial
Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results
ASH 2009: Shaji Kumar
Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study
ASH 2009: Shaji Kumar
Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation
ASH 2009: Shaji Kumar
Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study
ASH 2009: Sophie L. Corthals
Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma
ASH 2009: Sophie L. Corthals
Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma
ASH 2009: Sundar Jagannath, Overview
ASH 2009: Sundar Jagannath
The Combination of Vorinostat and Bortezomib Provides Long-Term Responses in Patients with Relapsed or Refractory Multiple Myeloma
ASH 2009: Swaminathan Padmanabhan
A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx)
ASH 2009: Taimur Sher
Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study
ASH 2009: Tomer Mark
T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma
ASH 2009: Tommasina Guglielmelli
Sequential Therapy with IMID’s in Relapsed-Refractory Multiple Myeloma Patients
ASH 2009: Ulf-Henrik Mellqvist
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
ASH 2009: Vincent Rajkumar, Current Approaches To Treatment Of Myeloma
ASH 2009
Hervé Avet Loiseau
Deletion of the 17p Chromosomal Region Is Associated with a Very Poor Outcome in Multiple Myeloma Independently of the Type of Treatment
ASH2009: Bank On A Cure® Update
Dr. Morie Gertz, Mayo Clinic, Rochester, Minnesota
Dr. Vincent Rajkumar, Mayo Clinic, Rochester, Minnesota
International Myeloma Working Group at ASH 2009
Neues vom ASH Kongress 2009
Un resumen de las presentaciones de ASH 2009
Una visione d’insieme dell’ASH 2009: Antonio Palumbo
Update From ASH 2009: Sequential Use Of Treatments vs.Combinations
Update from ASH 2009:
Novel Agents
Update from ASH 2009:
Sequential Use of Treatments vs. Combinations
Update from ASH 2009
Treating Elderly Patients
Update from ASH 2009
The Role of Transplant
Update from ASH 2009
Treating Younger Patients
ASCO 2010: A phase II study of a modified pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
ASCO 2010: Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
ASCO 2010: Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V).
Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients
Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma
IMWG Guidelines for the Management of Multiple Myeloma Patients Ineligible for Standard High-Dose Chemotherapy with Autologous Stem Cell Transplantation
Oncology Nurses Take the Lead in Providing Novel Therapy Guidelines for Multiple Myeloma
VELCADE® Adds Long-Term Overall Survival Benefit to Label
Genetic association with thalidomide mediated venous thrombotic events in myeloma indentified using targeted genotyping
Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations
IMWG Guidelines for the Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma
Overviews
|
|
|
"For the first time, we are seeing the role of the novel agents across the whole spectrum of myeloma" |
|
|
|
|
Paul Richardson, MD
Dana Farber Cancer Institute
Boston, Massachusetts |
|
|
|
|
Sundar Jagannath, MD
St. Vincents Comprehensive Cancer Center
New York, NY |
|
|
|
|
"This has been the most exciting and promising American Society of Hematology meeting in the last ten years" |
|
|
|
|
"There are many important presentations at this ASH meeting" |
|
|
|
|
"Today we reported on three drugs that will be part of future treatment choices for myeloma patients." |
|
International
|
|
|
 Meral Beksac, MD
Ankara University
Ibn Sina Hospital
Ankara, Turkey
|
|
|
|
|
 Heinz Ludwig, MD
Wilhelminenspital der Stadt
Wein, Österreich |
|
|
|
|
 Jean-Luc-Harousseau, MD
University Hospital Hotel-Dieu
Nantes France
|
|
|
|
|
 Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, España |
|
|
|
|
 Antonio Palumbo, MD
Ospedale Molinette
Torino, Italia |
|
|
|
|
 ד"ר מרטין אליס
מרכז רפואי ספיר
כפר-סבא, ישראל
|
|
Ask The Experts
|
|
|
Vincent Rajkumar, MD
Mayo Clinic
Rochester, Minnesota |
|
|
|
|
Paul Richardson, MD
Dana Farber Cancer Center
Boston, Massachusetts |
|
|
|
|
Jean-Luc Harousseau, MD
CHU Hotel Dieu
Nantes, France |
|
|
|
|
Antonio Palumbo, MD
Ospedale, Molinette
Torino, Italy |
|
|
|
|
Jean-Luc Harousseau, MD
CHU Hotel Dieu
Nantes, France |
|
|
|
|
Jesus San Miguel, MD
Universidad de Salamanca
Salamanca, Spain |
|
Revlimid
|
|
|
Andrzej J. Jakubowiak, MD
University of Michigan
Ann Arbor, MI |
|
|
|
|
Antonio Palumbio, MD
University Of Turin
Turin, Italy |
|
|
|
|
Antonio Palumbio, MD
University Of Turin
Turin, Italy |
|
|
|
|
Attaya Suvannasankha, MD
Indiana University School of Medicine
Indianapolis, IN |
|
|
|
|
Choon Kee Lee, MD
University of Colorado Health Sciences Center
Aurora, CO |
|
|
|
|
Edward Agura, MD
Baylor Sammons Cancer Center
Dallas, TX |
|
|
|
|
Evangelos Terpos, MD
Greek Myeloma Study Group
Athens, Greece |
|
|
|
|
Evangelos Terpos, MD
University of Athens School of Medicine
Athens, Greece
|
|
|
|
|
Evangelos Terpos, MD
University of Athens School of Medicine
Athens, Greece |
|
|
|
|
Evangelos Terpos, MD
University of Athens School of Medicine
Athens, Greece |
|
|
|
|
Federica Cavallo, MD
A.O.U. San Giovanni Battista
Torino, Italy |
|
|
|
|
Francesca Gay, MD
Mayo Clinic College of Medicine
Rochester, MN |
|
|
|
|
Francesca Gay, MD
Mayo Clinic College of Medicine
Rochester, MN |
|
|
|
|
|
Francesca Gay, MD
Mayo Clinic College of Medicine
Rochester, MN |
|
|
|
|
Maria-Victoria Mateos, MD
Hospital Universitario de Salamanca
Salamanca, Spain |
|
|
|
|
Paul Richardson, MD
Dana Farber Cancer Center
Boston, Massachusetts |
|
|
|
|
Philip L. McCarthy, MD
Roswell Park Cancer Institute
Buffalo, NY |
|
|
|
|
Preeti Khetarpal, MD
St. Vincent's Comprehensive Cancer Center
New York, NY |
|
|
|
|
Rachid Baz, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL |
|
|
|
|
Ruben Niesvizky, MD
Weill Cornell Medical Center
New York, New York |
|
|
|
|
Sagar Lonial
Emory University School of Medicine
Atlanta, Georgia |
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, MN |
|
|
|
|
Tommasina Guglielmelli, MD
University of Turin and San Luigi Hospital
Orbassano, Italy |
|
Thalomid
|
|
|
Antonio Palumbo, MD
A.O.U. San Giovanni Battista
Torino, Italy |
|
|
|
|
Elena Zamagni, MD
Bologna University School of Medicine
Bologna, Italy |
|
|
|
|
Evangelos Terpos, MD
University of Athens School of Medicine
Athens, Greece |
|
|
|
|
|
Evangelos Terpos, MD
University of Athens School of Medicine
Athens, Greece |
|
|
|
|
|
Federica Cavallo, MD
A.O.U. San Giovanni Battista
Torino, Italy |
|
|
|
|
|
Francesca Gay, MD
Mayo Clinic College of Medicine
Rochester, MN |
|
|
|
|
Gareth Morgan, MD
Royal Marsden Hospital
Surrey, UK |
|
|
|
|
Gareth Morgan
Royal Marsden Hospital
Surrey, UK |
|
|
|
|
Heinz Ludwig, MD
Center for Oncology and Haematology
Wilhelminenspital
Vienna, Austria |
|
|
|
|
Heinz Ludwig, MD
Center for Oncology and Hematology
Wilhelminenspital
Vienna, Austria |
|
|
|
|
|
Jean-Luc Harousseau, MD
Centre René Gauducheau
Nantes/St Herblain, France |
|
|
|
|
Joan Bladé, MD
Hospital Clinic
Barcelona, Spain |
|
|
|
|
Maria-Victoria Mateos, MD
Hospital Universitario de Salamanca
Salamanca, Spain |
|
|
|
|
Meral Beksac, MD
Ankara University
Ankara, Turkey
|
|
|
|
|
Michele Cavo, MD
Bologna University School of Medicine
Bologna, Italy |
|
|
|
|
Nilanjan Ghosh, MD
Johns Hopkins University
Baltimore, MD |
|
|
|
|
Prashant Kapoor, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
|
Preeti Khetarpal, MD
St. Vincent's Comprehensive Cancer Center
New York, NY |
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, MN |
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, MN
|
|
|
|
|
Taimur Sher, MD
Roswell Park Cancer Institute
Buffalo, NY |
|
|
|
|
Tomer Mark, MD
Weill Medical College of Cornell University
New York, NY
|
|
|
|
|
|
Tommasina Guglielmelli, MD
University of Turin and San Luigi Hospital
Orbassano, Italy |
|
|
|
|
|
Articles include:
* Plerixafor and Transplantation in Myeloma
* Phase II Study of Carfilzomib in Patients with Relapsed Myeloma
* IMWG Studies Patients Who Have Exhausted Their Treatment Options
* 2009 Kyle Award Given to Prof. Jean-Luc Harousseau
* Dr. Brian G.M. Durie Honored for Lifetime of Achievement in Myeloma
|
|
|
|
|
|
Articles include:
* Plerixafor and Transplantation in Myeloma
* Phase II Study of Carfilzomib in Patients with Relapsed Myeloma
* IMWG Studies Patients Who Have Exhausted Their Treatment Options
* 2009 Kyle Award Given to Prof. Jean-Luc Harousseau
* Dr. Brian G.M. Durie Honored for Lifetime of Achievement in Myeloma
|
|
Velcade
|
|
|
Andrzej J Jakubowiak, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI
|
|
|
|
|
|
Andrzej J. Jakubowiak, MD
University of Michigan
Ann Arbor, MI |
|
|
|
|
|
Antonio Palumbo, MD
A.O.U. San Giovanni Battista
Torino, Italy |
|
|
|
|
|
Choon Kee Lee, MD
University of Colorado Health Sciences Center
Aurora, CO |
|
|
|
|
Craig B. Reeder, MD
Mayo Clinic Arizona
Scottsdale, AZ |
|
|
|
|
David Siegel, MD
Hackensack University Medical Center
Hackensack, NJ |
|
|
|
|
Eric Sanchez, MD
Institute for Myeloma & Bone Cancer Research
West Hollywood, CA |
|
|
|
|
|
Evangelos Terpos, MD
University of Athens School of Medicine
Athens, Greece |
|
|
|
|
|
Evangelos Terpos, MD
University of Athens School of Medicine
Athens, Greece |
|
|
|
|
|
Evangelos Terpos, MD
University of Athens School of Medicine
Athens, Greece |
|
|
|
|
Francesca Gay, MD
A.O.U. San Giovanni Battista
Torino, Italy |
|
|
|
|
Francesca Gay, MD
A.O.U. San Giovanni Battista
Torino, Italy |
|
|
|
|
|
Heinz Ludwig, MD
Center for Oncology and Hematology
Wilhelminenspital
Vienna, Austria |
|
|
|
|
|
Heinz Ludwig, MD
Center for Oncology and Haematology
Wilhelminenspital
Vienna, Austria |
|
|
|
|
Hervé Avet Loiseau, MD
University Hospital of Nantes
Nantes, France |
|
|
|
|
|
Jean-Luc Harousseau, MD
Centre René Gauducheau
Nantes/St Herblain, France |
|
|
|
|
Jean-Luc Harousseau, MD
Centre René Gauducheau
Nantes/St Herblain, France |
|
|
|
|
Jesús F. San Miguel, MD
Hospital Universitario de Salamanca
Salamanca, Spain |
|
|
|
|
|
Joan Bladé, MD
Hospital Clinic
Barcelona, Spain |
|
|
|
|
|
Maria-Victoria Mateos, MD
Hospital Universitario de Salamanca
Salamanca, Spain |
|
|
|
|
Maria-Victoria Mateos, MD
Hospital Universitario de Salamanca
Salamanca, Spain |
|
|
|
|
|
Michele Cavo, MD
Bologna University School of Medicine
Bologna, Italy |
|
|
|
|
|
Nilanjan Ghosh, MD
Johns Hopkins University
Baltimore, MD |
|
|
|
|
Paul Richardson, MD
Dana Farber Cancer Institute
Boston, Massachusetts |
|
|
|
|
|
Paul Richardson, MD
Dana Farber Cancer Center
Boston, Massachusetts |
|
|
|
|
Paul Richardson, MD
Dana Farber Cancer Institute
Boston, Massachusetts |
|
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, MA |
|
|
|
|
Pieter Sonneveld, MD
Erasmus University Medical Center
Rotterdam Netherlands |
|
|
|
|
Ruben Niesvizky
Weill Cornell Medical Center
New York, New York |
|
|
|
|
Sagar Lonial
Emory University School of Medicine
Atlanta, Georgia |
|
|
|
|
Sagar Lonial, MD
mory University School of Medicine
Atlanta, GA |
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, MN |
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, MN |
|
|
|
|
Sophie L. Corthals
Erasmus University Medical Center
Rotterdam, Netherlands |
|
|
|
|
Sophie L. Corthals
Erasmus University Medical Center
Rotterdam, Netherlands |
|
|
|
|
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, NY |
|
|
|
|
|
Taimur Sher, MD
Roswell Park Cancer Institute
Buffalo, NY |
|
|
|
|
|
Tomer Mark, MD
Weill Medical College of Cornell University
New York, NY
|
|
|
|
|
Ulf-Henrik Mellqvist, MD
Sahlgrenska University Hospital
Gothenburg, Sweden |
|
New Agents
|
|
|
|
Andrzej J Jakubowiak, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI
|
|
|
|
|
Andrzej Jakubowiak, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI |
|
|
|
|
Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, NY |
|
|
|
|
Asher Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, NY |
|
|
|
|
David Siegel, MD
Hackensack University Medical Center
Hackensack, NJ |
|
|
|
|
|
David Siegel, MD
Hackensack University Medical Center
Hackensack, NJ |
|
|
|
|
|
David Siegel, MD
Hackensack University Medical Center
Hackensack, NJ |
|
|
|
|
Don Benson, MD
Ohio State University
Columbus, OH |
|
|
|
|
|
Edward Agura, MD
Baylor Sammons Cancer Center
Dallas, TX |
|
|
|
|
|
Heinz Ludwig, MD
Center for Oncology and Hematology
Wilhelminenspital
Vienna, Austria |
|
|
|
|
Irene M. Ghobrial, MD
Dana-Farber Cancer Institute
Boston, MA |
|
|
|
|
|
Jesús F. San Miguel, MD
Hospital Universitario de Salamanca
Salamanca, Spain |
|
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, MA |
|
|
|
|
|
Paul Richardson, MD
Dana Farber Cancer Institute
Boston, Massachusetts |
|
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, MA |
|
|
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, MA |
|
|
|
|
Ravi Vij, MD
Washington University School of Medicine
Saint Louis, Missouri
|
|
|
|
|
|
Ruben Niesvizky, MD
Weill Cornell Medical Center
New York, New York |
|
|
|
|
|
Sagar Lonial
Emory University School of Medicine
Atlanta, Georgia |
|
|
|
|
|
Sagar Lonial
Emory University School of Medicine
Atlanta, Georgia |
|
|
|
|
|
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, NY |
|
|
|
|
Swaminathan Padmanabhan, MD
University of Texas Health Science Center at San Antonio
San Antonio, TX |
|
Transplant
|
|
|
|
Antonio Palumbio, MD
University Of Turin
Turin, Italy |
|
|
|
|
|
Choon Kee Lee, MD
University of Colorado Health Sciences Center
Aurora, CO |
|
|
|
|
|
Elena Zamagni, MD
Bologna University School of Medicine
Bologna, Italy |
|
|
|
|
|
Evangelos Terpos, MD
University of Athens School of Medicine
Athens, Greece |
|
|
|
|
|
Francesca Gay, MD
A.O.U. San Giovanni Battista
Torino, Italy |
|
|
|
|
Joseph R. Mikhael, MD
Mayo Clinic
Scottsdale, AZ |
|
|
|
|
Kai Neben, MD
University of Heidelberg
Heidelberg, Germany |
|
|
|
|
|
Michele Cavo, MD
Bologna University School of Medicine
Bologna, Italy |
|
|
|
|
Morie Gertz, MD
Mayo Clinic
Rochester, Minnesota |
|
|
|
|
Nina Shah, MD
M.D. Anderson Cancer Center
Houston, TX |
|
|
|
|
|
Philip L. McCarthy, MD
Roswell Park Cancer Institute
Buffalo, NY |
|
|
|
|
|
Preeti Khetarpal, MD
St. Vincent's Comprehensive Cancer Center
New York, NY |
|
|
|
|
|
Shaji Kumar, MD
Mayo Clinic
Rochester, MN
|
|
Newly Diagnosed
|
|
|
|
Andrzej J. Jakubowiak, MD
University of Michigan
Ann Arbor, MI |
|
|
|
|
|
Antonio Palumbo, MD
A.O.U. San Giovanni Battista
Torino, Italy |
|
|
|
|
|
Antonio Palumbio, MD
University Of Turin
Turin, Italy |
|
|
|
|
|
Antonio Palumbio, MD
University Of Turin
Turin, Italy |
|
|
|
|
|
Attaya Suvannasankha, MD
Indiana University School of Medicine
Indianapolis, IN |
|
|
|
|
|
Craig B. Reeder, MD
Mayo Clinic Arizona
Scottsdale, AZ |
|
|
|
|
Evangelos Terpos, MD
Greek Myeloma Study Group
Athens, Greece |
|
|
|
|
|
Francesca Gay, MD
Mayo Clinic College of Medicine
Rochester, MN |
|
|
|
|
|
Francesca Gay, MD
Mayo Clinic College of Medicine
Rochester, MN |
|
|
|
|
|
Francesca Gay, MD
Mayo Clinic College of Medicine
Rochester, MN |
|
|
|
|
|
Gareth Morgan
Royal Marsden Hospital
Surrey, UK |
|
|
|
|
|
Heinz Ludwig, MD
Center for Oncology and Haematology
Wilhelminenspital
Vienna, Austria |
|
|
|
|
|
Heinz Ludwig, MD
Center for Oncology and Hematology
Wilhelminenspital
Vienna, Austria |
|
|
|
|
|
Jean-Luc Harousseau, MD
Centre René Gauducheau
Nantes/St Herblain, France |
|
|
|
|
|
Jean-Luc Harousseau, MD
Centre René Gauducheau
Nantes/St Herblain, France |
|
|
|
|
|
Maria-Victoria Mateos, MD
Hospital Universitario de Salamanca
Salamanca, Spain |
|
|
|
|
|
Maria-Victoria Mateos, MD
Hospital Universitario de Salamanca
Salamanca, Spain |
|
|
|
|
|
Maria-Victoria Mateos, MD
Hospital Universitario de Salamanca
Salamanca, Spain |
|
|
|
|
|
Meral Beksac, MD
Ankara University
Ankara, Turkey
|
|
|
|
|
|
Paul Richardson, MD
Dana Farber Cancer Center
Boston, Massachusetts |
|
|
|
|
Prashant Kapoor, MD
Mayo Clinic
Rochester, MN |
|
|
|
|
|
Rachid Baz, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL |
|
|
|
|
Ruben Niesvizky
Weill Cornell Medical Center
New York, New York |
|
|
|
|
|
Taimur Sher, MD
Roswell Park Cancer Institute
Buffalo, NY |
|
|
|
|
|
Tomer Mark, MD
Weill Medical College of Cornell University
New York, NY
|
|
Relapsed/Refractory
|
|
|
|
Andrzej J Jakubowiak, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI
|
|
|
|
|
|
Andrzej Jakubowiak, MD
University of Michigan Comprehensive Cancer Center
Ann Arbor, MI |
|
|
|
|
|
Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, NY |
|
|
|
|
|
Asher Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, NY |
|
|
|
|
|
David Siegel, MD
Hackensack University Medical Center
Hackensack, NJ |
|
|
|
|
|
David Siegel, MD
Hackensack University Medical Center
Hackensack, NJ |
|
|
|
|
|
David Siegel, MD
Hackensack University Medical Center
Hackensack, NJ |
|
|
|
|
|
Evangelos Terpos, MD
University of Athens School of Medicine
Athens, Greece
|
|
|
|
|
|
Evangelos Terpos, MD
University of Athens School of Medicine
Athens, Greece |
|
|
|
|
|
Evangelos Terpos, MD
University of Athens School of Medicine
Athens, Greece |
|
|
|
|
|
Federica Cavallo, MD
A.O.U. San Giovanni Battista
Torino, Italy |
|
|
|
|
|
Jesús F. San Miguel, MD
Hospital Universitario de Salamanca
Salamanca, Spain |
|
|
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, MA |
|
|
|
|
|
Paul Richardson, MD
Dana Farber Cancer Institute
Boston, Massachusetts |
|
|
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, MA |
|
|
|
|
|
Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, MA |
|
|
|
|
|
Ravi Vij, MD
Washington University School of Medicine
Saint Louis, Missouri
|
|
|
|
|
|
Ruben Niesvizky, MD
Weill Cornell Medical Center
New York, New York |
|
|
|
|
|
Sagar Lonial
Emory University School of Medicine
Atlanta, Georgia |
|
|
|
|
|
Sagar Lonial
Emory University School of Medicine
Atlanta, Georgia |
|
|
|
|
|
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, NY |
|
|
|
|
|
Swaminathan Padmanabhan, MD
University of Texas Health Science Center at San Antonio
San Antonio, TX |
|
Bank On A Cure
|
|
|
Brian Durie, MD
Cedars Sinai Comprehensive Cancer Center
Los Angeles, California |
|
|
|
|
Gareth Morgan, MD
Royal Marsden Hospital
Surrey, UK |
|
|
|
|
|
Gareth Morgan, MD
Royal Marsden Hospital
Surrey, UK |
|
|
|
|
|
Pieter Sonneveld, MD
Erasmus University Medical Center
Rotterdam Netherlands |
|
|
|
|
|
Sophie L. Corthals
Erasmus University Medical Center
Rotterdam, Netherlands |
|
|
|
|
|
Sophie L. Corthals
Erasmus University Medical Center
Rotterdam, Netherlands |
|
|
|
|
|
Evangelos Terpos, MD
Greek Myeloma Study Group
Athens, Greece |
|
|
|
|
|
Evangelos Terpos, MD
Greek Myeloma Study Group
Athens, Greece |
|
|
|
|
Herve Avet-Loiseau, MD
Institute de Biologie
Nantes, France |
|
|
|
|
Mariateresa Fulciniti, PhD
Dana-Farber Cancer Institute
Boston, MA
|
|
|
|
|
Martin Ellis, MD
Sapir Medical Center
Kfar-Saba, Israel |
|
|
|
|
Masood A Shammas, PhD
Dana-Farber Cancer Institute and Boston VA Healthcare System
West Roxbury, MA |
|
|
|
|
|
Prashant Kapoor, MD
Mayo Clinic
Rochester, MN |
|
|
button next to the volume control in the
lower right hand corner.
print
related videos
related articles